<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464228</url>
  </required_header>
  <id_info>
    <org_study_id>KO-TIP-002</org_study_id>
    <nct_id>NCT02464228</nct_id>
  </id_info>
  <brief_title>Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.</brief_title>
  <acronym>PTCL</acronym>
  <official_title>An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kura Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kura Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study designed to investigate antitumor activity in terms of objective response rate&#xD;
      (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will&#xD;
      be administered orally until disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in&#xD;
      subjects with relapsed or refractory PTCL. The first 18 subjects may be of the following PTCL&#xD;
      sub-types: PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma&#xD;
      (AITL), ALK-positive and negative anaplastic large cell lymphoma (ALCL), hepatosplenic T-cell&#xD;
      lymphoma, enteropathy-associate T-cell lymphoma (EATL), extranodal natural killer (NK) T-cell&#xD;
      lymphoma, nasal type and subcutaneous panniculitis-like T-cell lymphoma. The AITL expansion&#xD;
      cohort (N=32) will enroll only subjects with AITL. An additional cohort of patients (N=12)&#xD;
      expressing the wild type CXCL12 3' UTR will be enrolled in order to explore the benefits of&#xD;
      tipifarnib treatment observed in patients having an absence of this gene variation or single&#xD;
      nucleotide variation (SNV).&#xD;
&#xD;
      Tumor response assessments will be conducted according to Lugano Classification and/or mSWAT&#xD;
      criteria.&#xD;
&#xD;
      Tumor assessments will be performed approximately every 8 weeks (cycles 2-6) and at least&#xD;
      once approximately every 12 weeks thereafter (Cycles 9, 12, 15, etc.), and will continue&#xD;
      until disease progression. Subjects experiencing a complete response may be considered for&#xD;
      bone marrow transplantation. Upon disease progression, all subjects will be followed for&#xD;
      survival and the use of subsequent therapy. All subjects will be followed for safety during&#xD;
      treatment and up to approximately 30 days after treatment discontinuation or until before the&#xD;
      initiation of another anti-cancer therapy. Additional follow up may be implemented until the&#xD;
      subject recovers from any emergent treatment related toxicity or the adverse event is&#xD;
      considered irreversible by the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2015</start_date>
  <completion_date type="Actual">March 24, 2021</completion_date>
  <primary_completion_date type="Actual">March 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Response assessments according to Lugano Classification and/or mSWAT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the antitumor activity in terms of PFS in subjects with relapsed/refractory PTCL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the antitumor activity in terms of DOR in subjects with relapsed/refractory PTCL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that experience Adverse Events (AEs)</measure>
    <time_frame>Until 30 days following end of study</time_frame>
    <description>To evaluate the safety and tolerability of tipifarnib in subjects with relapsed/refractory PTCL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Relapsed or Refractory Peripheral T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tipifarnib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tipifarnib, oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipifarnib</intervention_name>
    <description>oral</description>
    <arm_group_label>Tipifarnib</arm_group_label>
    <other_name>Zarnesta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of PTCL according to the most recent edition of the World Health&#xD;
             Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues, as&#xD;
             follows:&#xD;
&#xD;
               1. Anaplastic large cell lymphoma (ALCL), ALK positive&#xD;
&#xD;
               2. ALCL, ALK negative&#xD;
&#xD;
               3. Angioimmunoblastic T-cell lymphoma (AITL)&#xD;
&#xD;
               4. Enteropathy-associated T-cell lymphoma&#xD;
&#xD;
               5. Extranodal natural killer (NK) T-cell lymphoma, nasal type&#xD;
&#xD;
               6. Hepatosplenic T-cell lymphoma&#xD;
&#xD;
               7. Peripheral T-cell lymphoma, not otherwise specified (NOS)&#xD;
&#xD;
               8. Subcutaneous panniculitis-like T-cell lymphoma&#xD;
&#xD;
          2. For enrollment into the AITL expansion cohort, subjects must have the diagnosis of&#xD;
             AITL, nodal PTCL with T-follicular helper phenotype or follicular PTC.&#xD;
&#xD;
          3. For enrollment into the CXCL12+ PTCL expansion cohort, subjects must have the&#xD;
             diagnosis of PTCL (a - h subtypes listed above, except AITL), consent to provide&#xD;
             buccal swabs for CXCL12 SNP testing, and be found to be CXCL12+ based on testing by a&#xD;
             Sponsor approved methodology.&#xD;
&#xD;
          4. Relapsed or are refractory to at least 1 prior systemic cytotoxic therapy. -Subjects&#xD;
             must have received conventional therapy as a prior therapy.&#xD;
&#xD;
          5. Subject has consented to provide at least 6 unstained tumor slides (10 preferred) or&#xD;
             an FFPE block for biomarker testing.&#xD;
&#xD;
          6. Subject has measurable disease as determined by the Lugano Classification and/or&#xD;
             mSWAT.&#xD;
&#xD;
          7. At least 2 weeks since the last systemic therapy regimen prior to enrollment.&#xD;
&#xD;
          8. At least 2 weeks since last radiotherapy if radiation was localized to the only site&#xD;
             of measurable disease, unless there is documentation of disease progression of the&#xD;
             irradiated site. Subjects must have recovered from all acute toxicities from&#xD;
             radiotherapy.&#xD;
&#xD;
          9. ECOG performance status of 0-2&#xD;
&#xD;
         10. Acceptable liver and renal function&#xD;
&#xD;
         11. Acceptable hematologic status&#xD;
&#xD;
         12. Female subjects must be either:&#xD;
&#xD;
               1. Of non-child-bearing potential (surgically sterilized or at least 2 years post-&#xD;
                  menopausal); or&#xD;
&#xD;
               2. If of child-bearing potential, subject must use an adequate method of&#xD;
                  contraception consisting of two-barrier method or one barrier method with a&#xD;
                  spermicide or intrauterine device. Both females and male subjects with female&#xD;
                  partners of child- bearing potential must agree to use an adequate method of&#xD;
                  contraception for 2 weeks prior to screening, during, and at least 4 weeks after&#xD;
                  last dose of trial medication. Female subjects must have a negative serum or&#xD;
                  urine pregnancy test within 72 hours prior to start of trial medication.&#xD;
&#xD;
               3. Not breast feeding at any time during the study.&#xD;
&#xD;
         13. Written and voluntary informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of any of the following:&#xD;
&#xD;
               1. Precursor T-cell lymphoma or leukemia&#xD;
&#xD;
               2. Adult T-cell lymphoma/leukemia (ATLL)&#xD;
&#xD;
               3. T-cell prolymphocytic leukemia&#xD;
&#xD;
               4. T-cell large granular lymphocytic leukemia&#xD;
&#xD;
               5. Primary cutaneous type anaplastic large cell lymphoma&#xD;
&#xD;
               6. Mycosis fungoide/Sezary syndrome&#xD;
&#xD;
          2. Ongoing treatment with an anticancer agent not contemplated in this protocol.&#xD;
&#xD;
          3. Prior treatment (at least 1 full treatment cycle) with an FTase inhibitor.&#xD;
&#xD;
          4. Any history of clinically relevant coronary artery disease or myocardial infarction&#xD;
             within the last 3 years.&#xD;
&#xD;
          5. Known central nervous system lymphoma.&#xD;
&#xD;
          6. Stem cell transplant less than 3 months prior to enrolment.&#xD;
&#xD;
          7. Non-tolerable &gt; Grade 2 neuropathy or evidence of unstable neurological symptoms&#xD;
             within 4 weeks of Cycle 1 Day 1.&#xD;
&#xD;
          8. Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1,&#xD;
             without complete recovery.&#xD;
&#xD;
          9. Other active malignancy requiring therapy such as radiation, chemotherapy, or&#xD;
             immunotherapy.&#xD;
&#xD;
         10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy.&#xD;
&#xD;
             Known infection with HIV, or an active infection with hepatitis B or hepatitis C.&#xD;
&#xD;
         11. Subjects who have exhibited allergic reactions to tipifarnib, or structural compounds&#xD;
             similar to tipifarnib or to its excipients. This includes hypersensitivity to&#xD;
             imidazoles, such as clotrimazole, ketoconazole, miconazole and others in this drug&#xD;
             class.&#xD;
&#xD;
         12. Concomitant disease or condition that could interfere with the conduct of the study,&#xD;
             or that would, in the opinion of the investigator, pose an unacceptable risk to the&#xD;
             subject in this study.&#xD;
&#xD;
         13. The subject has legal incapacity or limited legal capacity.&#xD;
&#xD;
         14. Dementia or significantly altered mental status that would limit the understanding or&#xD;
             rendering of informed consent and compliance with the requirements of this protocol.&#xD;
&#xD;
         15. Unwillingness or inability to comply with the study protocol for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bridget Martell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University, Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia de Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 Octubre de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTCL-NOS</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>AITL</keyword>
  <keyword>Nodal T-follicular helper phenotype</keyword>
  <keyword>ALCL</keyword>
  <keyword>Hepatosplenic T-cell lymphoma</keyword>
  <keyword>EATL</keyword>
  <keyword>Extranodal (NK) T-cell lymphoma</keyword>
  <keyword>Wild Type CXCL12 3' UTR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

